Altre lingue BeiGene, Ltd.

Azioni

BGNE

US07725L1026

Mercato chiuso - Nasdaq Altri mercati azionari 22:00:00 25/04/2024			Variaz. 5gg	Var. 1 gen.
148,6 ^USD	+3,08%		+12,58%	-17,63%

23/04	Aggiornamento settoriale: i titoli del settore sanitario salgono nelle contrattazioni pomeridiane	MT
23/04	BeiGene afferma che Tislelizumab ha ottenuto l'approvazione della Commissione Europea per il trattamento del tumore al polmone non a piccole cellule; le azioni aumentano	MT

Altre lingue

Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!

Registrazione 100% gratuita

Globaler Onkologie-Innovator BeiGene präsentiert auf der ASCO-Jahrestagung 2024 neue Daten aus dem gesamten Portfolio für Hämatologie und solide Tumore	13:12
BeiGene, innovateur mondial en oncologie, présente de nouvelles données sur l’ensemble de son portefeuille en hématologie et en tumeurs solides lors de la réunion annuelle de l’ASCO 2024	13:11
Global Oncology Innovator BeiGene Highlights New Data across Hematology and Solid Tumor Portfolio at 2024 ASCO Annual Meeting	24/04
BeiGene erhält von der EU-Kommission die Zulassung für Tislelizumab zur Behandlung von nicht kleinzelligem Lungenkrebs	24/04
BeiGene reçoit l’approbation de la Commission européenne pour le tislelizumab dans le traitement du cancer du poumon non à petites cellules	24/04
Sector Update: Health Care Stocks Rise in Afternoon Trading	23/04
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer; Shares Rise	23/04
BeiGene Shares Rise 7% After European Approval of Tislelizumab Cancer Treatment	23/04
Technology Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Higher in Tuesday Trading	23/04
BeiGene Says Tislelizumab Gets European Commission's Approval to Treat Non-Small Cell Lung Cancer	23/04
BeiGene Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	23/04
BeiGene, Ltd. Receives European Commission Approval for Tislelizumab as Treatment for Non-Small Cell Lung Cancer	23/04
BeiGene to Award Shares Worth $15 Million to 11 Directors	17/04
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04
Western Drugmakers Seeking Alternative Suppliers as US Looks to Restrict Chinese Biotech	11/04
BeiGene Opens New Factory in Guangzhou for Antibody-Drug Conjugates	10/04
Beigene Shrinks Loss by 56% in 2023	29/03
Tech Stocks Lead Asian Equities Traded in the US as American Depositary Receipts Slightly Lower in Friday Trading	22/03
BeiGene, Ltd. Announces Executive Changes	20/03
BeiGene reçoit l'approbation de la FDA pour TEVIMBRA® dans le traitement du carcinome épidermoïde de l’œsophage avancé ou métastatique après une chimiothérapie	15/03

Non ci sono risultati per questa ricerca

Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Altre lingue BeiGene, Ltd.

Azioni

BGNE

US07725L1026

Altre lingue

Filtri